5:34 PM · 28 October 2025

DE40: DAX near 1-week high 📈Deutsche Borse lags, SUSS MicroTec slides 23%

Key takeaways
DE40
Indices
-
-
SUESS MicroTec
Stocks
SMHN.DE, SUESS MicroTec SE
-
-
Deutsche Boerse
Stocks
DB1.DE, Deutsche Boerse AG
-
-
Key takeaways
  • DAX fluctuates at 1-week high
  • Symrise and SUSS MicroTec slide after earnings
  • Nordex shares surge 19% 
  • Deutsche Borse stock well below EMA200 despite solid earnings report

Sentiments across the German stock market are slightly better today, amid positive sentiments on Wall Street. European stocks rise. German chancellor, Friedrich Merz backed up the Pan-European stock exchange initiative, aimed to rival US and Chinese stock markets.

DE40

Futures on DAX (DE40) are up almost 0.3% today, rising above 24400 points, respecting EMA50 (the orange line). 

 

Source: xStation5

SUSS MicroTec (D1 interval)

 

Deutsche Bank has lowered its price target for SUSS MicroTec SE from €41 to €36, keeping a Hold rating after the company issued its second profit warning of 2025. While sales came in solid — around €118 million, about 4–5% above expectations — margins collapsed, revealing the real pain point. The gross margin dropped to 33.1%, well below the 38–39% range analysts had forecast, pulling the EBIT margin down to just 10.5%. According to Deutsche Bank, the sharp decline reflects both a less favorable product mix and ramp-up costs from the new Taiwan fab, which are weighing on near-term profitability. Top-line growth isn’t the issue — margins are. Actually, a stock is almost 30% below its EMA200.

 

Source: xStation5

Deutsche Borse (D1 interval) Stock Beats Expectations, Calms Fears on Treasury Drag

Deutsche Boerse AG (DB1:GR) posted a solid Q3 2025 performance, edging past analyst forecasts and easing investor concerns over weak treasury results. Net revenue rose 3% year-over-year, while revenue excluding treasury results jumped 7%, signaling underlying business strength. Treasury income fell 19%, but the drop was less severe than markets anticipated.

  • Tight cost control helped — expenses were 2% below estimates, lifting profitability. As a result, EBITDA beat consensus by 4% and EPS by 5%, marking a welcome return to earnings momentum. Deutsche Boerse reaffirmed its full-year 2025 outlook, currently trading at 18.3× 2026 EPS and 12× EV/EBITDA.
  • Deutsche Börse delivered a strong third quarter, surprising analysts with better-than-expected results even amid low stock market volatility. The exchange operator earned €473 million in profit, a 6% increase year-over-year, exceeding consensus forecasts. 
  • According to new CFO Jens Schulte, earnings excluding treasury results rose 7%, showing the company’s resilience despite cyclical pressures in trading activity. For the full year, Deutsche Börse remains on track to meet its 2025 targets. Management continues to expect net revenue (ex-treasury) to climb roughly 9% to about €5.2 billion, while EBITDA should reach around €2.7 billion, up from €2.35 billion in the prior year.

In short, even with calmer markets, Deutsche Börse is proving it can generate steady growth — a reassuring signal for long-term. Deutsche Bank analyst maintained a Buy rating and €291 price target, saying the results “put an end to the recent negative earnings trends” and provide a strong setup for the December Capital Markets Day.

 
 
 

Source: xStation5

Symrise (SY1.DE, D1 interval)

 

Symrise Reports Slight Revenue Dip but Reaffirms Profit Targets

Symrise AG, the German producer of fragrances and flavorings, reported a modest decline in third-quarter revenue, reflecting slower market dynamics in parts of its portfolio. Revenue came in at €1.22 billion, down from €1.26 billion a year earlier, though organic sales still grew 1.4%. For the first nine months of the year, Symrise generated €3.78 billion in revenue, slightly below last year’s €3.82 billion, corresponding to 2.6% organic growth.

The company adjusted its full-year guidance, narrowing its organic growth forecast to 2.3%–3.3% (previously 3%–5%) but maintaining its EBITDA margin target around 21.5%. Looking ahead, Symrise reaffirmed its 2028 mid-term goals — targeting an organic compound annual growth rate (CAGR) of 5%–7% and an EBITDA margin between 21% and 23%. Despite near-term headwinds, Symrise continues to emphasize stable profitability and disciplined execution toward its long-term growth plan.

Source: xStation5

28 October 2025, 10:00 PM

Palantir and Nvidia Join Forces in Advanced Artificial Intelligence Development

28 October 2025, 9:41 PM

Microsoft and OpenAI: Strategic Restructuring and the Upcoming Report as an AI Market Barometer

28 October 2025, 8:40 PM

Cameco Shares Hit Record Highs Following Strategic Partnership Announcement with the US!

28 October 2025, 7:22 PM

UnitedHealth Group: Q3 2025 Results and Outlook Point to a Recovery!

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.

Join over 1 700 000 investors from around the world